BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36409930)

  • 1. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
    Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
    Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
    Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
    Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
    Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
    PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.
    Fernández P; Perez-Aso M; Smith G; Wilder T; Trzaska S; Chiriboga L; Franks A; Robson SC; Cronstein BN; Chan ESL
    Am J Pathol; 2013 Dec; 183(6):1740-1746. PubMed ID: 24266925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
    Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
    Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
    FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
    Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
    FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity.
    Losenkova K; Takeda A; Ragauskas S; Cerrada-Gimenez M; Vähätupa M; Kaja S; Paul ML; Schmies CC; Rolshoven G; Müller CE; Sandholm J; Jalkanen S; Kalesnykas G; Yegutkin GG
    Cell Mol Life Sci; 2022 Feb; 79(3):152. PubMed ID: 35212809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.